icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Metabolics at IAS 2017: bone, CVD, Comorbidities, Brain, Fatty Liver
  Switch to Dolutegravir Noninferior to Continued PI in Older Group With Heart Risk - (08/04/17)
(NEAT-022) At 48 weeks total cholesterol, non-HDL cholesterol, triglycerides, and LDL cholesterol all rose slightly in the PI group while falling in the dolutegravir group, and between-group differences were all statistically significant. The total-to-HDL ratio fell 7% in the dolutegravir arm and rose 0.4% in the PI arm (P < 0.001). Serious adverse event rates did not differ significantly between study arms at 48 weeks.
Bone Mineral Density at the Hip Declines Twice as Quickly Among HIV-Infected Women than Men - (08/14/17) ....."The majority of our study population were less than 50 years old, and only 15% of female participants were menopausal at baseline. Thus, with aging, the rate of BMD decline among HIV-infected women is expected to be even more pronounced.....Among men, neither lumbar spine nor femoral neck BMD was associated with HCV....Among women: metabolic syndrome was associated with lower lumbar spine BMD (estimate -0.0193, SD 0.0061, p=0.0025)"
Zoledronic Acid Boosts Bone Density More Than Switch From TDF - (08/03/17)
Sub-Study 202094 of SWORD-1 and SWORD-2: Switch From TDF-Containing Regimen to DTG + RPV Improves Bone Mineral Density and Bone Turnover Markers Over 48 Weeks - (07/26/17)
Heightened Risk of Peripheral Arterial Disease With HIV in Veterans (07/27/17)
HIV mediated immunosenescence in young adults infected at birth [and HIV+ adults too despite undetectable VL] - (07/31/17)
Adults With Renal Impairment Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Have Improved Renal and Bone Safety Through 144 Weeks - (08/02/17)
T cell immune exhaustion in gut-associated lymphoid tissue during treated primary HIV infection: Implications for HIV persistence - (08/02/17)
More and earlier cardiovascular events (CVE) and shorter overall survival (OS) in HIV-positive patients (HIV+) compared to the general population differ by sex - (08/03/17)
Atrial Fibrillation at an Earlier Age in People With HIV Infection - (08/06/17)
Prevalence of Comorbidities and Impact of HIV and Comorbidities on Health Care Resource Utilization - (08/03/17)
....2-3 times more bone disease in HIV+ vs HIV-neg, 2-8 times more kidney disease in HIV, among people over 65 yrs bone disease is double that vs in HIV-neg and kidney disease is 8 times more prevalent among HIV+; total health care costs without ART are much higher among HIV+ vs HIV-neg, with ARTs included total costs per year per patient were 9 times greater for HIV+ and 3 times higher when excluding ART costs. Health care services costs per patient per year were double for HIV+ vs HIV-neg because more services were used like office visits & hospitalizations, and also more ED use & ICU use.
Fatty Acid Profiles Altered by HIV Infection Persist Despite Suppressive Antiretroviral Therapy (ART) and are Associated with Immune Activation in the ACTG 5248 Study - (08/10/17)
Higher HDL, better brain? Higher HDL cholesterol is associated with better cognition in a cohort of older persons living with HIV infection - (08/10/17)
Cerebral Small Vessel Disease Signal Similar in Older Men With vs Without HIV - (08/08/17)
Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study - (07/25/17)
IAS: Fatty Liver in HIV+ at IAS - (08/05/17)
Inflammation and Obesity Tied to Incident Diabetes in Veterans With HIV - (08/07/17)
Dual ARTs & New HIV Drugs New HIV & HCV Drugs at IAS / Dual ARTs / Fatty Liver in HIV+ - (08/09/17)
Key Studies......
A Phase 3 Randomized Controlled Clinical Trial of Bictegravir in a Fixed Dose Combination, B/F/TAF, vs DTG/ABC/3TC in Treatment-Naïve Adults at Week 48 - (07/23/17)
Phase 3 Randomized, Controlled, Clinical Trial of Bictegravir Coformulated With FTC/TAF in a Fixed-Dose Combination vs Dolutegravir + FTC/TAF in Treatment-Naïve HIV-1-Positive Adults: Week 48 Results - (07/27/17)
Fixed-Dose Combination of Doravirine/Lamivudine/TDF is Non-Inferior to Efavirenz/Emtricitabine/TDF in Treatment-Naïve Adults With HIV-1 Infection: Week 48 Results of the Phase 3 DRIVE-AHEAD Study - (07/25/17)
Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17)
Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxilfumarate regimens to the single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofoviralafenamide (D/C/F/TAF) in virologicallysuppressed, HIV-1-infected adults through 24 weeks: EMERALD Study - (07/25/17)
Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, in Combination With Tenofovir Disoproxil Fumarate/Emtricitabine, in Previously Untreated HIV-1 Infection Through Week 96 - (07/24/17)
HIV & the Brain
Microglial Cells That Are Latently Infected By HIV Are Activated By Inflammatory Stimuli and Induce Neuronal Damage - (08/09/17)
Prevalence over time and predictive factors of HIV-associated neurocognitive disorder (HAND) in HIV-positive patients - (08/09/17)
Assessing depression's impact on neurocognitive performance in the NAMACO study - (08/09/17)
IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention

Paris, France
July 23-26 2017